TriSalus Life Sciences (NASDAQ:TLSI) Lowered to Sell Rating by Wall Street Zen

Key Points

• TriSalus Life Sciences has been downgraded from a "hold" to a "sell" rating by analysts at Wall Street Zen.
• The company's recent earnings report indicated an EPS of ($0.27), missing the consensus estimate of ($0.22) by ($0.05) while achieving revenues of $11.21 million.
• Institutional investors and hedge funds collectively own 2.58% of TriSalus Life Sciences' stock, with notable increases in positions from several firms during the last quarter.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Sunday.

TriSalus Life Sciences Stock Performance

Shares of TLSI opened at $4.70 on Friday. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $5.88. The stock has a fifty day moving average price of $4.63 and a two-hundred day moving average price of $5.08. The company has a market cap of $234.39 million, a price-to-earnings ratio of -3.98 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The business had revenue of $11.21 million during the quarter, compared to analysts' expectations of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. As a group, research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $29,000. JPMorgan Chase & Co. lifted its position in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after acquiring an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of TriSalus Life Sciences in the second quarter worth $47,000. Charles Schwab Investment Management Inc. bought a new position in shares of TriSalus Life Sciences in the first quarter worth $55,000. Finally, New York State Common Retirement Fund bought a new position in TriSalus Life Sciences in the second quarter valued at $108,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.